Inhibikase Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Inhibikase Therapeutics's estimated annual revenue is currently $804k per year.
- Inhibikase Therapeutics's estimated revenue per employee is $100,500
- Inhibikase Therapeutics's total funding is $1.3M.
Employee Data
- Inhibikase Therapeutics has 8 Employees.
- Inhibikase Therapeutics grew their employee count by 0% last year.
Inhibikase Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Clinical Operations | Reveal Email/Phone |
2 | Head Program Management | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Clinical Trial Manager | Reveal Email/Phone |
5 | Clinical Trial Associate | Reveal Email/Phone |
Inhibikase Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $24.5M | 122 | 8% | N/A | N/A |
#2 | $10.7M | 53 | -17% | N/A | N/A |
#3 | $9.2M | 46 | 2% | N/A | N/A |
#4 | $24.1M | 120 | 5% | N/A | N/A |
#5 | $7.2M | 36 | -20% | N/A | N/A |
#6 | $27.7M | 138 | -30% | N/A | N/A |
#7 | $39.8M | 198 | 37% | N/A | N/A |
#8 | $0.5M | 5 | 25% | $50M | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $10.3M | 51 | 11% | N/A | N/A |
What Is Inhibikase Therapeutics?
Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.
keywords:N/A
$1.3M
Total Funding
8
Number of Employees
$804k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Inhibikase Therapeutics News
Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference. Thu, April 21, 2022, 1:05 PM...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and...
BOSTON and ATLANTA, March 31, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage...
Other Companies in ATLANTA
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 8 | -33% | $135M |
#2 | $0.6M | 8 | N/A | N/A |
#3 | $0.1M | 8 | -11% | $8.7M |
#4 | $0.6M | 8 | N/A | N/A |
#5 | $0.1M | 8 | -33% | $5.9M |